Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Invizyne Technologies, Inc.: Invizyne's Nasdaq IPO Marks New Era of Biomanufacturing | 56 | GlobeNewswire (Europe) | Monrovia, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially... ► Artikel lesen | |
Mi | Invizyne Technologies stock climbs 13% following $15M IPO | 6 | Seeking Alpha | ||
Mi | Invizyne Technologies Opens At $11.10, IPO Priced At $8 | 5 | Investing.com | ||
INVIZYNE TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
Mi | Invizyne Technologies, Inc.: Invizyne Technologies Begins Trading on NASDAQ | 60 | GlobeNewswire (Europe) | Monrovia, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and... ► Artikel lesen | |
Di | Invizyne Technologies Inc - 10-Q, Quarterly Report | - | SEC Filings | ||
Di | Invizyne Technologies, Inc.: Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024 | 50 | GlobeNewswire (Europe) | Monrovia, CA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and... ► Artikel lesen | |
Di | Biomanufacturing company Invizyne Technologies prices IPO at $8 | 5 | Renaissance Capital | ||
Di | Invizyne Technologies prices $15M U.S. IPO | 7 | Seeking Alpha | ||
21.10. | Invizyne Technologies Inc - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
05.10. | Invizyne Cuts IPO Size And Lifts Offering Price | 1.061 | AFX News | WASHINGTON (dpa-AFX) - Invizyne Technologies announced that it has decreased the size of shares and increased the price range of its planned initial public offering.The company, which develops... ► Artikel lesen | |
05.10. | Biomanufacturing company Invizyne Technologies increases range and decreases shares ahead of $15 IPO deal size | 3 | Renaissance Capital | ||
04.10. | Invizyne Technologies Inc - S-1/A, General form for registration of securities | 4 | SEC Filings | ||
19.09. | Invizyne Technologies Inc - S-1/A, General form for registration of securities | 4 | SEC Filings | ||
07.09. | Biomanufacturing company Invizyne Technologies cuts share offering by 13% and adds rights ahead of $15 million IPO | 1 | Renaissance Capital | ||
06.09. | Invizyne Technologies Inc - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
01.08. | Invizyne Technologies Inc - 8-A12B, Registration of securities | - | SEC Filings | ||
01.08. | Invizyne Technologies Inc - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
11.07. | MDB Capital Holdings, LLC: MDB Capital Announces Record Date and Expected Timing for Initial Public Offering for Invizyne Technologies | 1 | GlobeNewswire (USA) | ||
22.05. | Invizyne Technologies Inc - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
07.05. | Invizyne Technologies, Inc.: Invizyne Technologies Expands Leadership Team Ahead of Proposed Offering and Listing on Nasdaq | 3 | GlobeNewswire (Europe) | Michael Heltzen appointed as CEO bringing 20 years of global commercial leadership experience and a track record of successful launches and exitsAdditional industry veterans join in key roles including... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,180 | -0,06 % | ANALYSE-FLASH: UBS belässt Qiagen auf 'Neutral' - Ziel 50 Euro | ZÜRICH (dpa-AFX) - Die Schweizer Großbank UBS hat Qiagen nach Quartalszahlen auf "Neutral" mit einem Kursziel von 50 Euro belassen. Der Labordienstleister habe dank des starken organischen Umsatzwachstums... ► Artikel lesen | |
EVOTEC | 8,630 | +0,76 % | Aktien Frankfurt: Dax nähert sich wieder Rekordhoch | FRANKFURT (dpa-AFX) - Anleger haben am Montag Mut geschöpft und den Dax in Richtung seines bisherigen Rekordes getrieben. Der deutsche Leitindex stieg gegen Mittag um 1,31 Prozent auf 19.467,76 Punkte.... ► Artikel lesen | |
BIONTECH | 100,10 | -5,21 % | ANALYSE-FLASH: Goldman hebt Biontech auf 'Buy' - Ziel hoch auf 137 Dollar | NEW YORK (dpa-AFX) - Die US-Investmentbank Goldman Sachs hat Biontech von "Neutral" auf "Buy" hochgestuft und das Kursziel von 90 auf 137 US-Dollar angehoben. Analyst Chris Shibutani bezieht in seiner... ► Artikel lesen | |
GUBRA | 86,80 | +33,54 % | AKTIONÄR-Depotwert Gubra wird optimistischer - richtungsweisende Daten in Kürze | Der dänische Wirkstoffforscher Gubra hat ein weiteres wachstumsstarkes Quartal abschließen können - vor allem dank dynamischer Entwicklungen in den Forschungsbereichen Adipositas und Nierenerkrankungen.... ► Artikel lesen | |
DYNE THERAPEUTICS | 30,670 | -10,19 % | Dyne Therapeutics GAAP EPS of -$0.96 misses by $0.25 | ||
AVIDITY BIOSCIENCES | 51,23 | -2,51 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 47,180 | +1,46 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements | Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,76 | -0,02 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
ADMA BIOLOGICS | 20,540 | -4,33 % | ADMA Biologics-Aktie erreicht Allzeithoch von 21,25 US-Dollar | ||
HARMONY BIOSCIENCES | 33,160 | -2,04 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 19,790 | +1,64 % | Summit Therapeutics Aktie: Verunsicherung steigt! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnet einen bemerkenswerten Aufschwung an der Börse. Die Aktie schloss am 9. November 2024 bei 21,41 USD, was einem Anstieg von 1,47%... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 7,135 | -2,39 % | Recursion Pharmaceuticals: Recursion and Exscientia Shareholders Approve the Proposed Combination | Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated closeSalt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq:... ► Artikel lesen | |
MODERNA | 36,930 | -7,50 % | Moderna mit überraschend gutem Quartal - Covid-Impfung bleibt gefragt | CAMBRIDGE (dpa-AFX) - Der Covid-Impfstoffhersteller Moderna hat ein unerwartet gutes Quartal hinter sich. Der neueste Booster der Amerikaner wurde drei Wochen früher als im letzten Jahr zugelassen... ► Artikel lesen | |
HUMACYTE | 4,855 | -9,08 % | Humacyte, Inc: Humacyte Third Quarter 2024 Financial Results and Business Update | - FDA review of acellular tissue engineered vessel (ATEV) BLA for the Treatment of Vascular Trauma is ongoing - - Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access... ► Artikel lesen | |
BB BIOTECH | 40,850 | -1,57 % | BB Biotech Aktie: Weiterhin auf Erfolgskurs! | Die BB Biotech-Aktie verzeichnete am 1. November 2024 einen beachtlichen Kurssprung auf 39,85 EUR und überschritt damit die bedeutsame 50-Tage-Linie. Diese positive Entwicklung deutet auf ein gesteigertes... ► Artikel lesen |